Hematology

Latest News

The rarity of PH in MPN/AML, coupled with variable mechanisms and response to therapy, makes standardized risk tools and protocols difficult to implement. | Image Credit: Dr_Microbe - stock.adobe.com
AML Relapse Mirrors Pulmonary Hypertension Worsening in Rare Case

August 14th 2025

A rare case report describes a young woman whose relapse of AML following MPN coincided with severe worsening of pulmonary hypertension, highlighting the need for vigilant cardiopulmonary monitoring in hematologic malignancies.

Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com
QRISK3 Tool Predicts Thrombotic Events in ET, PV

August 8th 2025

BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com
New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

August 7th 2025

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

July 31st 2025

The analysis combined data from 3 major CLL clinical trials—ELEVATE-TN, ELEVATE-RR, and ASCEND—and postmarketing surveillance from a global database. | Image credit: laszlo - stock.adobe.com
Acalabrutinib Shows Low Cardiac Toxicity in Clinical, Real-World Data

July 31st 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission
February 21st 2018

Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission

Laura Joszt, MA
Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Denosumab Effectively Prevented Skeletal-Related Events in Multiple Myeloma
February 16th 2018

Denosumab Effectively Prevented Skeletal-Related Events in Multiple Myeloma

Laura Joszt, MA
New research published in The Lancet Oncology found that denosumab was noninferior to zoledronic acid for time to skeletal-related events in patients with newly diagnosed multiple myeloma.
Site Logo
February 15th 2018

Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?

Inmaculada Hernandez, PharmD, PhD Samuel W. Bott, BS Anish S. Patel, BS Collin G. Wolf, BS Alexa R. Hospodar, BS Shivani Sampathkumar, BS William H. Shrank, MD, MSHS
The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
Study Documents Chronic Pain Associated With Sickle Cell Disease
February 14th 2018

Study Documents Chronic Pain Associated With Sickle Cell Disease

Allison Inserro
Sickle cell disease (SCD), the most common inherited blood disorder in the United States, is marked by episodes of acute pain, but there is increasing recognition that it can transition to chronic persistent SCD pain. A recent study found that the presence of pain on 3 or more days a week is independently associated with worse patient-reported pain interference and anxiety.
Adding Daratumumab to Standard-of-Care Has Clinical Benefits in Newly Diagnosed Patients With Multiple Myeloma
February 14th 2018

Adding Daratumumab to Standard-of-Care Has Clinical Benefits in Newly Diagnosed Patients With Multiple Myeloma

Laura Joszt, MA
The addition of daratumumab to standard-of-care regimens used to treat multiple myeloma, such as bortezomib, melphalan, and prednisone, decreased the risk of disease progression or death in newly diagnosed patients who were ineligible for autologous stem-cell transplantation.
New Imaging Technique Reveals Inner Structure of Red Blood Cells
February 9th 2018

New Imaging Technique Reveals Inner Structure of Red Blood Cells

Allison Inserro
Researchers have used super-resolution microscopy to unveil the geodesic mesh that supports the outer membrane of a red blood cell, in a discovery that could eventually help uncover how the malaria parasite hijacks this mesh when it invades and eventually destroys red blood cells. The work was published in the latest issue of Cell Reports.
Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival
February 9th 2018

Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival

Laura Joszt, MA
A long-term follow-up analyzing the toxic effects and results from a phase 1 clinical trial of adult patients with relapsed B-cell acute lymphoblastic leukemia (ALL) who were treated with CD19-specific chimeric antigen receptor (CAR) T cells found patients with low disease burden had a longer medial overall survival and a lower incidence of toxicity.
Site Logo
February 1st 2018

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
February 1st 2018

Ibrutinib Is More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia

Jaime Rosenberg
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
CAR T-Cell Therapy Effective for Children With ALL, Updated Study Results Show
February 1st 2018

CAR T-Cell Therapy Effective for Children With ALL, Updated Study Results Show

Allison Inserro
Final updated results of the pivotal phase 2 study that led to last year’s FDA approval of the first chimeric antigen receptor (CAR) T-cell therapy were published Wednesday in the New England Journal of Medicine.
Site Logo
February 1st 2018

Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
ICER Report: Despite High Price, Emicizumab for Hemophilia A Cuts Costs
January 31st 2018

ICER Report: Despite High Price, Emicizumab for Hemophilia A Cuts Costs

Jaime Rosenberg
While the wholesale acquisition cost of the hemophilia A drug is approximately $482,000 for the first year of treatment and $448,000 for subsequent years, a draft report found that the drug would reduce the budget by approximately $1.85 billion per patient annually for patients aged 12 and older. In patents aged 12 and younger, emicizumab at wholesale acquisition cost pricing would reduce the budget by approximately $720,000 per patient annually.
Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer
January 27th 2018

Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer

Laura Joszt, MA
Every year, central lines are associated with causing blood infections in an estimated 400,000 patients with cancer. However, new research has found that changes in the microbiome may be responsible for some or many of the infections usually attributed to central lines.
Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM
January 22nd 2018

Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM

Laura Joszt, MA
The FDA has approved a supplemental New Drug Application to add new overall survival (OS) data for carfilzomib (Kyprolis). The label will now show that carfilzomib and dexamethasone reduced the risk of death by 21% and increased OS by 7.6 months compared with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).
Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds
January 20th 2018

Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds

Laura Joszt, MA
Despite years of stability, patients with monoclonal gammopathy of undetermined significance (MGUS) are at risk of progressing to multiple myeloma or another blood cancer, according to a long-term follow-up study published in New England Journal of Medicine. MGUS usually causes no problems, but it is a precursor to cancer.
Study Finds Protein Markers May Better Predict Drug Response in Patients With AML Than Genetic Mutations
January 18th 2018

Study Finds Protein Markers May Better Predict Drug Response in Patients With AML Than Genetic Mutations

AJMC Staff
A study finds that protein markers may be a better predictor of drug response than genetic mutation are in patients with acute myeloid leukemia (AML). As a result, some patients who could benefit from treatment may not be eligible under current approval specifications.
Julie Wolfson: Supporting AYAs Before and After Treatment
January 14th 2018

Julie Wolfson: Supporting AYAs Before and After Treatment

The challenges that adolescents and young adults face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.
Promacta Earns Breakthrough Therapy Designation by FDA for Severe Aplastic Anemia
January 11th 2018

Promacta Earns Breakthrough Therapy Designation by FDA for Severe Aplastic Anemia

Samantha DiGrande
Recently, the FDA granted a breakthrough therapy designation to eltrombopag (Promacta, Novartis) for combination use with standard immunosuppressive therapy as a first-line treatment for patients with severe aplastic anemia (SAA).
Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib
January 7th 2018

Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib

AJMC Staff
A subset of patients with chronic lymphocytic leukemia (CLL) with highly expressed CD49d have poorer outcomes while on Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B-cell receptor (BCR) signals. However, a team of researchers may have found a way to treat these patients.
Study Examines Cost-Effectiveness in Multiple Myeloma Treatments
January 6th 2018

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

Kaitlynn Ely
New drugs to treat multiple myeloma (MM) have provided clinical benefits, but a study published in the Journal of Managed Care & Specialty Pharmacy found not all of them can be considered cost effective.
Study Examines Cost-Effectiveness in Multiple Myeloma Treatments
January 6th 2018

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

Kaitlynn Ely
New drugs to treat multiple myeloma (MM) have provided clinical benefits, but a study published in the Journal of Managed Care & Specialty Pharmacy found not all of them can be considered cost effective.
Higher Rates of Cardiovascular Adverse Events in Patients With MM Treated With Carfilzomib
January 4th 2018

Higher Rates of Cardiovascular Adverse Events in Patients With MM Treated With Carfilzomib

Jaime Rosenberg
Carfilzomib was associated with higher rates of all-grade and high-grade cardiovascular adverse events (CVAE), and both later trial phase and higher doses of carfilzomib were associated with higher rates of CVAE, according to a study in JAMA Oncology.
Risk Model Predicts Mortality in Patients With AML
December 31st 2017

Risk Model Predicts Mortality in Patients With AML

Allison Inserro
Acute myeloid leukemia (AML) is the most common form of acute leukemia and has a poor 5-year survival rate, especially among older people. Cancer researchers have created a model that can predict mortality after AML treatment, so that it can help guide decision-making for patients and providers.
Determining Discharge Criteria for Pediatric Patients Admitted With Febrile Neutropenia
December 30th 2017

Determining Discharge Criteria for Pediatric Patients Admitted With Febrile Neutropenia

AJMC Staff
Management of pediatric oncology patients with febrile neutropenia and hospitalization duration currently vary by institution and by provider. A poster presented at the 59th American Society of Hematology Annual Meeting reviewed pediatric hematology/oncology patients who were admitted with febrile neutropenia to determine discharge and release, as well as subsequent readmission within the next 4 days.
Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma
December 29th 2017

Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma

The last 5 years have seen a host of new drugs approved for multiple myeloma, improving survival times for patients, explained Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.
Dr Stephen Schuster on Institution Commitments to Deliver CAR T Therapies
December 28th 2017

Dr Stephen Schuster on Institution Commitments to Deliver CAR T Therapies

Deciding to administer CAR T-cell therapies is an institutional commitment that requires educating all clinicians who will be involved and partnerships with other organizations, said Stephen Schuster, MD, of the Perelman School of Medicine.
Long-Term Effects of G-CSF Use in Patients With Cyclic Neutropenia
December 26th 2017

Long-Term Effects of G-CSF Use in Patients With Cyclic Neutropenia

Jaime Rosenberg
Based on long-term observations, granulocyte colony-stimulating factor utilization is a safe and effective treatment to prevent infections and improve quality of life in patients with cyclic neutropenia, according to an analysis in The New England Journal of Medicine.
Diagnosing Congenital Neutropenia
December 23rd 2017

Diagnosing Congenital Neutropenia

Laura Joszt, MA
Physicians caring for patients with severe congenital neutropenia should be ready to detect issues with multiple systems in the body, explained Seth Corey, MD, of the Virginia Commonwealth University and the Massey Cancer Center & Children's Hospital of Richmond, during a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia.
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 19th 2017

New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017

Laura Joszt, MA
The FDA was busy in 2017, with a number of notable approvals, including the first chimeric antigen receptor T-cell treatment. In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, employees from the FDA presented data on 5 new drug approvals in leukemia and lymphoma in 2017.
Site Logo
December 18th 2017

Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs

Surabhi Dangi-Garimella, PhD
Opioids are commonly precribed for the treatment of both acute and chronic pain.
<1
...
202122232425262728>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo